• Revenue growth drivers: The company recorded a 19.1% growth rate—its highest in four years—driven by the addition of 32 labs and over 2,000 collection centers in the last two years, along with launching more than 100 new tests.
• Margin and guidance: EBITDA margin reached 31%, supported by a 2–3% direct pricing benefit from CGHS and ECHS revisions. Management is confident of achieving mid-teens revenue growth and expects full-year margins to exceed the prior year's levels.
• Pricing hike strategy: Having taken no price increases in 3.5 years, the company does not anticipate raising prices in the next two to three quarters unless extreme cost inflation requires passing expenses to customers.
• Genomics revenue contribution: The genomics business continues to account for less than 5% of revenue due to lower penetration and specialized test volumes, though management considers it a major long-term growth opportunity.